Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from Covid-19 in hospitalized patients in a clinical trial.
The US drugmaker said the drug, in combination with Gilead Sciences Inc's Remdesivir, met the main goal of shortening recovery when compared to Remdesivir alone.
(Published 14 September 2020, 11:33 IST)
JOIN US